Sugi Predict

Sugi Predict / Compounds / SCHEMBL2884817

SCHEMBL2884817

SCHEMBL2884817

Cc1cc(Cl)c2cc(C(=O)O)ccc2n1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.62
▸ TDP1 Q9NUW8 3/20 0.53
▸ MAPT P10636 2/20 0.51
▸ ALDH1A1 P00352 4/20 0.50
▸ HPGD P15428 4/20 0.50
▸ POLB P06746 4/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ HSP90AA1 P07900 1/20 0.47
▸ ESR2 Q92731 1/20 0.47
▸ TSHR P16473 1/20 0.47
▸ TP53 P04637 1/20 0.47
▸ KDM4E B2RXH2 3/20 0.45
▸ GAA P10253 1/20 0.45
▸ CDH1 P12830 1/20 0.45
▸ APC P25054 1/20 0.45
▸ CTNNB1 P35222 1/20 0.45
▸ TCF7L2 Q9NQB0 1/20 0.45
▸ NPC1 O15118 3/20 0.45
▸ RAB9A P51151 3/20 0.45
▸ MEN1 O00255 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30251661 1.00 LMNA (0.62) LMNATDP1MAPTALDH1A1HPGD
Hydrochloric Acid SCHEMBL18109900 0.98 LMNA (0.60) LMNATDP1MAPTALDH1A1HPGD
SCHEMBL31000776 0.89 TDP1 (0.51) LMNATDP1MAPTALDH1A1HPGD
SCHEMBL13754217 0.89 LMNA (0.60) LMNAMAPTALDH1A1HPGDPOLB
SCHEMBL20504398 0.89 TDP1 (0.51) LMNATDP1MAPTALDH1A1HPGD
SCHEMBL20733144 0.89 LMNA (0.60) LMNATDP1MAPTALDH1A1HPGD
SCHEMBL5093476 0.84 TP53 (0.65) LMNATDP1MAPTALDH1A1HPGD
SCHEMBL30251615 0.84 TP53 (0.65) LMNATDP1MAPTALDH1A1HPGD
SCHEMBL14016671 0.84 LMNA (0.55) LMNAMAPTESR2TP53SMN1; SMN2
SCHEMBL30050282 0.83 TDP1 (0.56) TDP1MAPTALDH1A1HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND NATIONAL UNIVERSITY CORPORATION KOBE UNIVERSITY (JP) 2025-03-20 — — US disclosed
CN-115335378-B Monoacylglycerol lipase modulators 詹森药业有限公司 2025-03-04 — — CN disclosed
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2024-07-11 — — US disclosed
US-11891387-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2024-02-06 — — US disclosed
EP-4126860-A1 MONOACYLGLYCEROL LIPASE MODULATORS Janssen Pharmaceutica NV (BE) 2023-02-08 — — EP disclosed
WO-2023008577-A1 RAS/RAF BINDING INHIBITOR COMPOUND 国立大学法人神戸大学 2023-02-02 — — WO disclosed
US-20220372030-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2022-11-24 — — US disclosed
CN-115335378-A Monoacylglycerol lipase modulators 詹森药业有限公司 2022-11-11 — — CN disclosed
WO-2021191359-A1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2021-09-30 — — WO disclosed
US-7846925-B2 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2010-12-07 — — US disclosed
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES LABORATOIRES SERONO S.A. (CH) 2009-12-10 — — US disclosed
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives MERCK SERONO SA (CH) 2006-06-08 — — US disclosed
US-20050222225-A1 Use of compounds for increasing spermatozoa motility APPLIED RESEARCH SYSTEMS ARS HOLDING NV (NL) 2005-10-06 — — US disclosed
EP-1549644-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2005-07-06 — — EP disclosed
EP-1531813-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY Applied Research Systems ARS Holding N.V. (AN) 2005-05-25 — — EP disclosed
WO-2004007491-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2004-01-22 — — WO disclosed
WO-2004006916-A1 USE OF COMPOUNDS FOR INCREASING SPERMATOZOA MOTILITY APPLIED RESEARCH SYSTEMS ARS HOLDING NV (AN) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090306069-A1 AZOLIDINONE-VINYL FUSED-BENZENE DERIVATIVES ZAP70, BRCA1, ZYX LMNA 3252/4885TDP1 1837/4885MAPT 3408/4885
US-20250091994-A1 RAS/RAF BINDING INHIBITOR COMPOUND BRAF, RAF1, NRAS LMNA 4297/4885TDP1 3630/4885MAPT 4513/4885
US-20240228484-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP LMNA 1185/4885TDP1 1064/4885MAPT 2438/4885
US-11891387-B2 Monoacylglycerol lipase modulators MGLL, LPL, PNLIP LMNA 1185/4885TDP1 1064/4885MAPT 2438/4885
US-20050222225-A1 Use of compounds for increasing spermatozoa motility CATSPER1, PI4KB, MAN2B2 LMNA 1094/4885TDP1 623/4885MAPT 4185/4885
US-20220372030-A1 MONOACYLGLYCEROL LIPASE MODULATORS MGLL, LPL, PNLIP LMNA 1185/4885TDP1 1064/4885MAPT 2438/4885
US-20060122176-A1 Azolidinone-vinyl fused-benzene derivatives BRCA1, ZAP70, F13B LMNA 3373/4885TDP1 1744/4885MAPT 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.